Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
Arcutis Biotherapeutics Total Current Liabilities Related Terms
Arcutis Biotherapeutics Total Current Liabilities Historical Data
* Premium members only.
The historical data trend for Arcutis Biotherapeutics's Total Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcutis Biotherapeutics Total Current Liabilities Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
What does a Total Current Liabilities of $160.3 Mil mean?
Arcutis Biotherapeutics (ARQT) has a Total Current Liabilities of $160.3 Mil as of Jun. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Arcutis Biotherapeutics and its competitors.
Is Arcutis Biotherapeutics' Total Current Liabilities too high?
Arcutis Biotherapeutics' current Total Current Liabilities is $160.3 Mil. Overall, Arcutis Biotherapeutics has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arcutis Biotherapeutics' Total Current Liabilities compare to IDYA and NAMS?
Arcutis Biotherapeutics' Total Current Liabilities of $160.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Arcutis Biotherapeutics and its competitors. Arcutis Biotherapeutics's current Total Current Liabilities is $160.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcutis Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Arcutis Biotherapeutics (ARQT) is currently considered Modestly Undervalued. The stock's GF Value™ is $30.59, compared to a current price of $25.08 — trading 18% below its estimated fair value. The current Total Current Liabilities is $160.3 Mil. Arcutis Biotherapeutics' overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Arcutis Biotherapeutics (ARQT), the current Total Current Liabilities is $160.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcutis Biotherapeutics (ARQT) Overvalued in 2026?
Based on GuruFocus' analysis, Arcutis Biotherapeutics stock appears to be undervalued.
The current stock price of $25.08 is trading 18% below its estimated GF Value™ of $30.59.
GuruFocus considers Arcutis Biotherapeutics to be Modestly Undervalued.
Key valuation signals for ARQT:
Total Current Liabilities: $160.3 Mil
GF Value™: $30.59 vs. price of $25.08 (18% below fair value)
No single metric tells the full story. See the ARQT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
56GF Score
Get the complete analysis for ARQT
Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARQT has been successfully added to your 
